Radiopharma Is Becoming a Registration-Geography Business
The most interesting biotech development of the last forty-eight hours is not a drug approval or a late-stage efficacy surprise.…
Decoding the Science of Life
The most interesting biotech development of the last forty-eight hours is not a drug approval or a late-stage efficacy surprise.…
The most important biotech development of the last forty-eight hours is not a drug approval or another trial readout. It…
The most consequential biotech development of the last forty-eight hours is not a flashy new target or another early-stage platform…
The most interesting biotech development of the last forty-eight hours is not a new mechanism in early discovery or a…
The most important biotech development of the last forty-eight hours is not another deal, a manufacturing expansion, or a platform…
Biotech investors have heard a decade of claims about how artificial intelligence would compress timelines, improve hit rates, and redesign…
The landscape of regenerative medicine reached a significant milestone this week as MEDIPOST Inc. announced the treatment of the first U.S.…
In biotech, investors often overreact to early efficacy hints and underappreciate the strategy hiding underneath them. The more interesting July…
The most revealing life-sciences development of the last two days is not a trial readout or a regulatory letter. It…
Biotech investors often reserve their emotional energy for glamorous failures: breakthrough drugs that miss endpoints, gene-editing platforms that stumble, cell…
The global biotech ecosystem is currently living through a critical data paradox. Researchers have unprecedented access to high-resolution biological information…